Risk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer: insights from the ARCA registry
Authors' conclusion
This real-world data did not identify differences in the risk of new primary cancer, locoregional progression or metastasis across different DMARDs strategies in patients with RA and prior cancer.
Study context
- Population
- Real-world patients with rheumatoid arthritis (RA) and prior cancer, nationwide ARCA registry11,022 years cumulative exposure
- Participants
- 728 patients
- Exposure
- b/tsDMARD strategies vs csDMARDs
- Outcome
- New primary cancer, locoregional progression or metastasis during follow-up
Methodological detailsnationwide registry, adjusted Cox regression
- Nationwide registry
- Adjusted Cox regression
Main finding
As reported in the abstract
All cancers (new primary cancer, locoregional progression or metastasis)
Each group vs csDMARDsAdjusted hazard ratio (95% CI)
TNFi
0.94(0.73–1.21)
IL6-inhibitors
1.03(0.61–1.74)
CD20 inhibitors
0.81(0.46–1.42)
tsDMARDs
0.6(0.26–1.4)
CTLA4-analogue
0.74(0.41–1.34)
- Cancer events
- 80
- Overall cancer incidence rate per 1000 person-years
- 7.3 (95% CI 5.8 to 9.0)
Observational data: associations, not effects.
Further findings
Cancer risk adjusted for duration of exposure, line of advanced therapy or prior cancer status
- No differences in cancer risk observed
Original publication
Risk of new primary cancer, locoregional progression or metastasis associated with bDMARDs and tsDMARDs in patients with rheumatoid arthritis and prior cancer: insights from the ARCA registry. RMD Open. Published 25 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →